Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control. ...

Related Keywords

Harith Rajagopalan ,Beth Brett ,Timothy Kieffer ,Stephen Jasper ,Elisa Davidson ,Fractyl Health ,Exchange Commission ,Fractyl Health Inc ,Fractyl Health Rejuva ,Gilmartin Group ,Company Rejuva ,Corporate Communications ,While The Company ,Nasdaq ,Fractyl Health Chief Scientific ,Clinical Trial Application ,Private Securities Litigation Reform Act ,Chief Financial Officer ,